A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)
NCT 05086692 Brief Summary This is a Phase 1/2, multi-center, open-label, dose-escalation…
Read more arrow_forwardNCT 05086692 Brief Summary This is a Phase 1/2, multi-center, open-label, dose-escalation…
Read more arrow_forwardNCT 05923008 Brief Summary This is a phase 1/2 multicenter, open-label, first-in-human…
Read more arrow_forwardNCT 05763004 Brief Summary The goal of this clinical trial is to…
Read more arrow_forwardNCT 05608876 Brief Summary A Phase II, open label, single arm…
Read more arrow_forwardNCT 04534205 Brief Summary An open-label, controlled, multi-site, interventional, 2-arm, Phase…
Read more arrow_forwardNCT 05858164 Brief Summary Researchers are looking for a better way…
Read more arrow_forwardNCT 05999994 Brief Summary The main purpose of the master is to…
Read more arrow_forwardNCT 06170190 Brief Summary This is a multicentre, open-label, first-in-human, phase 1/2…
Read more arrow_forwardNCT 04801095 Brief Summary This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics,…
Read more arrow_forwardNCT 05332574 Brief Summary This is a Phase 1/2 study of GB263T…
Read more arrow_forward